Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial

Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $7

Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and raises the price target from $6 to $7.

Atea Pharmaceuticals Q2 EPS $(0.41) Beats $(0.56) Estimate

Atea Pharmaceuticals shares are trading lower. The company announced topline findings from its pivotal North American Phase 3 C-BEYOND clinical trial evaluating its oral antiviral therapy for chronic hepatitis C virus infection.

Gilead’s Trodelvy-Keytruda Combo Gets EU Approval for Metastatic Breast Cancer

Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up?

The Invesco Pharmaceuticals ETF (PJP) offers concentrated exposure to 29 pharma giants with better historical returns and lower volatility, while the Invesco Nasdaq Biotechnology ETF (IBBQ) provides broader diversification across 251 holdings at a lower expense ratio of 0.19% versus 0.57%. Despite IBBQ's cost advantage, PJP is recommended as the better buy due to its significantly larger asset base ($512.6M vs $81M), which addresses liquidity concerns.

KLA, Snowflake, Airbnb And A Health Care Stock On CNBC’s ‘Final Trades’

Joshua Brown chose Snowflake Inc., while Rob Sechan picked KLA Corp and Brian Belski recommended Gilead Sciences. Joseph Terranova went for Airbnb.